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Background: The purpose of this study was to compare perioperative outcomes in patients who underwent video-
assisted thoracoscopic surgery or robot-assisted thoracoscopic surgery and assess the feasibility of robotic-assisted
thymectomy for the treatment of Masaoka stage I.
Methods: We evaluated the short-term outcomes of 46 patients who underwent surgery for Masaoka stage I
thymoma without myasthenia gravis between January 2009 and June 2012. Of these patients, 25 received unilateral
video-assisted thoracoscopic surgery (VATS group) and the rest 21 recieved unilateral robotic-assisted thoracoscopic
surgery (RATS group). We evaluated the duration of surgery, amount of intraoperative blood loss, duration of chest
drainage, duration of postoperative hospital stay, hospitalization costs, postoperative complications and oncological
outcomes.
Results: The duration of surgery was not significantly different between the two groups. Intraoperative blood loss
volumes did not differ significantly between the VATS and RATS groups (86.8 mL and 58.6 mL, respectively;
P=0.168). The postoperative hospital stay was significantly shorter in the RATS group (3.7 days vs. 6.7 days; P <0.01),
and the postoperative pleural drainage volume of the RATS group was significantly less than VATS group (1.1 days
vs. 3.6 days; P <0.01). No patients in the RATS group needed conversion to open surgery. However, in the VATS
series, one patient had conversion to an open procedure. No surgical complications were observed except that one
case had pulmonary atelectasis in the RATS group and one case developed pneumonia after surgery. Use of robot
is much more expensive than video. No early recurrence was observed in both groups.
Conclusions: Robotic thymectomy is feasible and safe for Masaoka stage I thymoma. RATS is equally minimally
invasive as VATS and results in a shorter drainage period and reduced hospital stay compared with the VATS
approach.
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Thymomas are rare intrathoracic neoplasms of the thymus
with an annual incidence of approximately 0.15 per
100,000 person-years [1]. Surgical intervention remains
the only curative treatment and is traditionally performed
through a median sternotomy, with complete resection of
the tumor, thymus, thymic cervical extensions, and the
surrounding perithymic fat [2,3]. With the advent of* Correspondence: 839974703@qq.com
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reproduction in any medium, provided the orimproved optics and computer-assisted surgical systems,
minimally invasive thymectomies by video-assisted or
robotic techniques are becoming increasingly popular [4].
We herein present our operative method of unilateral
RATS thymectomy for the treatment of Masaoka stage I
thymoma without myasthenia gravis. We compared the
short-term outcomes of patients undergoing RATS and
those undergoing VATS thymectomy.Methods
We retrospectively reviewed our experience on thymec-
tomy for the treatment of stage I thymoma at theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the patients in the VATS and
RATS groups
VATS RATS P value
Patients (n) 25 21
Gender (male:female) 13:12 9:12 0.536
Age (mean±SD) (years) 53.4±5.4 52.7±7.8 0.74
Range (years) (43-62) (37-66)
Stage (Masaoka I) 25 21
Tumor size (mm) 30.4±7.9 29.1±7.7 0.56
Approach (right/left) 16/9 19/2
RATS, robotic-assisted thoracoscopic surgery; VATS, video-assisted thoracoscopic
surgery.
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Between January 2009 and June 2012, a total of 532
patients underwent resection of primary thymic tumors
with curative intent. Of these patients, 46 (22 men and
24 women) with a pathological diagnosis of Masaoka
stage I thymoma without myasthenia gravis who con-
secutively underwent VATS or RATS were selected for
this study. The performance of VATS and RATS was ap-
proved by hospital local ethics committee, and written
informed consents were obtained from all patients.
Twenty-five patients underwent thymoma resection
using VATS, and the other 21 underwent RATS.
In each case, preoperative computed tomography (CT)
demonstrated that the anterior mediastinal tumor, which
was histologically confirmed as thymoma after surgery,
demonstrated features highly suggestive of thymoma
without signs of invasion to the surrounding structures.
VATS or RATS was indicated for thymomas of <5 cm.
All patients were anesthetized using a double-lumen
tube for split-lung ventilation and were placed left- or
right-side up at 30°. For VATS, the diseased side of the
thoracic cavity was approached using a three-port tech-
nique. The diseased side of the thymus was dissected from
the inferior pole to the superior pole, and the contralateral
thymus was dissected after the left brachiocephalic vein
had been exposed. The thymic veins were divided with
ultrasonic shears or electric cautery for dissection. The
procedure in the VATS group was conventional.
For RATS, the first incision was generally performed
in the fifth intercostal space at the anterior axillary line.
Thus, the camera was inserted to explore the chest
cavity, and carbon dioxide was inflated (ranging between
4 and 8_mmHg) to enlarge the operating space and
safely perform the other port incisions: at the anterior
axillary line at the third intercostal and at the fifth inter-
costal space at the mid-clavicular line. The operator’s
right hand held ultrasonic shears to perform the dissec-
tion, and the left hand held Cadiere forceps (EndoWrist;
Intuitive Surgical, Inc, Sunnyvale, CA, USA), an atrau-
matic instrument for grasping the normal thymus. The
normal thymic tissue and perithymic fat were used to
grasp and place traction on the tumor, avoiding direct
manipulation of the tumor to minimize the risk of
capsule damage.
After inspection of the thymus gland and the thym-
oma, the dissection generally started inferiorly, first from
the left side at the pericardiophrenic angle; it then con-
tinued on the right side, from the retrosternal area. The
right mediastinal pleura and right phrenic nerve were
identified, permitting safe dissection of the right inferior
horn under direct visualization of the nerve. Conse-
quently, the dissection continued upward to the neck
until the superior horns were identified. The thymic
veins were identified and separately clipped. The lesionswere removed with endoscopic pouches from the cavity
through the port incision in the mid-axillary region. If
necessary, the incision was enlarged (3 cm maximum).
No additional utility incision was used. A drainage tube
was inserted, generally 32 inches. All thymus tissue and
perithymic fat were dissected according to the Masaoka
criteria [5], and the completeness of the thymectomy
was assessed by macroscopic inspection of the thymic
bed and specimen.
We evaluated the duration of surgery, amount of
intraoperative blood loss, duration of chest drainage,
duration of postoperative hospital stay, postoperative
complications, and hospitalization costs. The diagnoses
of all resected thymomas, surgical margins, and Masaoka
stage were confirmed by histological examination. Size,
as shown by the maximal diameter of the tumor within
the resected specimen, was measured. Recurrence of
thymoma was evaluated by CT of the chest 6 and
12months after surgery and once yearly thereafter.
Statistical analysis
The data are reported as means±standard deviations.
Statistical analysis was performed with SPSS 16.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Probability
values were generated with the chi-squared test (categor-
ical data) and the unpaired t-test (noncategorical data).
A probability value of P <0.05 was considered to be
statistically significant.
Results
The preoperative characteristics of the two groups of
patients are shown in Table 1. The VATS group com-
prised 13 men and 12 women with a mean age of 53.3
years. The RATS group included 9 men and 12 women
with a mean age of 52.7 years. In the VATS group, 16
patients were approached from the right thoracic cavity,
and nine patients were approached from the left. Surgi-
cal outcomes in the VATS and RATS groups are shown
in Table 2. The duration of surgery and volume of
intraoperative blood loss were not significantly different
Table 2 Surgical outcomes of the patients in the VATS and RATS groups
VATS RATS P value
Patients (n) 25 21
Duration of surgery (min) 103.6 ± 36 96.2 ± 39.8 0.51
Blood loss (mL) 86.8 ± 97.1 58.6 ± 20.6 0.168
Postoperative pleural drainage (days) 3.6 ± 1.2 1.1 ± 1 <0.01
Postoperative hospital stay (days) 6.7 ± 1.4 3.7 ± 1.1 <0.01
Hospitalization costs (CNY) or USD 37,376.6 ± 8,226.3 or 53,099.3 ± 14,556 <0.01
6,097 ± 1,342 8,662 ± 2,375
Converted to open surgery 1 0
Blood transfusion 1 0
Postoperative complications 1 1
CNY, Chinese Yuan; RATS, robotic-assisted thoracoscopic surgery; VATS, video-assisted thoracoscopic surgery.
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hospital stay was shorter in the RATS group (3.7 days in
the RATS group compared with 6.7 days in the VATS
group; P <0.01). The median postoperative stay was
shorter in the RATS group (4 days vs. 7 days, P <0.01).
The criteria for chest tube removal were similar for both
groups. Chest tubes were removed when the drainage
output volume declined to <100 mL in a 24-h period.
The mean postoperative pleural drainage volume was
significantly decreased in the RATS group (1.1 days vs.
3.6 days; P <0.01). However, the mean hospitalcosts
were higher in the RATS group (USD 6,097±1,342 vs.
USD 8662±2,375 P <0.01) possibly because of expense
of equipment.
The da Vinci system enables surgeons to accurately
dissect the left thymic lobe from right-sided access in most
patients. No patients in the RATS group underwent con-
version to open surgery. No surgical complications, such
as massive bleeding, were observed in this series with the
exception of one case of pulmonary atelectasis in a male
patient 2 days after surgery.
Alternatively, in the VATS group, conversion to an open
procedure was required in only one patient because of
intraoperative injury of the left innominate vein and one
case of postoperative pneumonia occurred. In both
groups, the surgical margins were free of tumor tissue. No
early recurrence was observed during the postoperative
follow-up period of 17.5 months (range, 6-48 months) in
the RATS group and 25.2 months (range, 6-48 months) in
the VATS group.
Discussion
The open surgical approach has generally been accepted
as the gold standard for thymoma resection [6-9]. How-
ever, over the last decades, both thoracoscopic and,
more recently, robotic approaches have been introduced
into the thoracic field and also applied to thymectomy.
Several data were published regarding minimally invasivethymectomy, reporting interesting outcomes and em-
phasizing less operative trauma, shorter hospital stays,
preserved pulmonary function, and superior cosmetic
results [10-13]. However, only a few major series have
reported the surgical results of RATS surgery for thym-
oma [14-16]. In the surgical treatment of non-invasive
thymoma, the choice of RATS or VATS remains
controversial.
Our short-term surgical outcomes showed the safety
and efficacy of RATS for Masaoka stage I thymoma. The
duration of surgery was the same in both groups, and
there was no statistically significant difference between
the two groups (P=0.168) in the amount of blood lost.
However, RATS thymectomy was less invasive, as indi-
cated by the significant decrease in the mean or median
postoperative stay in the RATS group. Furthermore,
there were no serious postoperative complications in the
RATS group. In addition, no case was converted to open
surgery, and no case required blood transfusion. Al-
though the follow-up period was short, there was no
early recurrence of thymoma. Our results suggest that
RATS thymectomy is tolerated in patients with early-
stage thymoma.
An important point is that we use ultrasonic devices
in RATS. Great care must be taken to avoid vascular and
nervous injuries. Bleeding is the most serious complica-
tion and should be kept in mind during this operation.
Special attention must be paid because venous drainage
of the gland to the innominate vein involves thin vessels;
each must be isolated from the thymic veins, coagulated,
and cut with an ultrasonic device to minimize the
amount of bleeding. In the RATS series, no patients
experienced conversion to an open procedure. However,
in the VATS series, one patient experienced conversion
to an open procedure because of injury to the left
innominate vein during electric cautery for dissection.
Although small, this tool is excellent in terms of hand-
ling and indispensable for this operating method.
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some criticisms of minimally invasive approaches still
exist. First, the possibility of tumor spread into the chest
cavity has been reported in some papers [6,17,18].
Agasthian et al. [19] reported a local recurrence rate of
3.4% in patients who underwent VATS thymectomy for
thymoma, while two recent papers compared VATS and
open approaches for thymomas. Cheng et al. [20]
observed no local or pleural disease recurrence for stage
II thymoma in either the open or VATS groups. Similar
results were published by Pennathur et al. [19] in a
larger comparative study, reporting no significant differ-
ence in disease recurrence or overall survival between
the two groups. In our small series, despite the fact that
the follow-up period was short, we observed no local or
pleural recurrence. We believe that the robotic system
facilitates differentiation of thymoma from normal
thymic tissue and allows for safe manipulation. Never-
theless, an important factor that likely affected the suc-
cess of the minimally invasive approach is the dimension
of the lesion. In our series, the mean thymoma dimen-
sion was 30.4±7.9 mm in VATS and 29.05±7.7 mm in
RATS, similar to the dimensions reported in the above-
mentioned comparative studies of the VATS approach
[19,20]. However, the indolent nature of thymomatous
disease necessitates a long follow-up [21] of 10 years to
evaluate the survival and disease-free rates. Thus, further
multi-institutional studies involving larger series are
necessary.
Because high costs are one of the main points of criti-
cism voiced in connection with robotic-assisted opera-
tions, we recently evaluated the hospitalization costs of
thymectomy for various minimally invasive approaches.
Use of robots is significantly more expensive, and we
demonstrated high costs compared with VATS (P <0.01).
These high costs are primarily caused by the expensive
robotic instruments, which can be reused only a limited
number of times [22].
The present study has some limitations, including its
retrospective nature, which may have resulted in a selec-
tion bias. Moreover, the study sample was small and the
follow-up period short. However, this is an initial experi-
ence resulting from gained skill in robotic surgery for
thymoma, and the main aim was to analyze the safety
and technical feasibility of the robotic approach for
early-stage thymomas. In fact, few data regarding the
robotic approach with a focus on thymoma have been
published, and our small series is the largest one to our
knowledge.
Conclusion
This preliminary study demonstrates the safety and
feasibility of robotic thymectomy for thymoma, with no
mortality, low morbidity, and no nerve or vessel injury.RATS is equally minimally invasive as VATS and results
in a shorter drainage period and reduced hospital stay
compared with VATS approach. Nevertheless, it is hoped
that randomized multi-institutional trials with long-term
follow-up will be designed to compare the trans-sternal,
video-assisted thoracoscopic, and robotic approaches
and evaluate the oncological outcomes.
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